GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

AES · Jun 30, 2025

AES CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000874761-25-000075General Corporate
Capex intensity70thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

46.65% · OPTIONAL · VALID

Operating cash generation95thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

34.19% · OPTIONAL · VALID

Revenue growth45thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

-2.96% · CORE · VALID

Inventory pressure65thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

22.66% · OPTIONAL · VALID

Gross margin5thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

15.87% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History35 statesSelf-history eligible
Period transition

What moved in the state?

Capex Intensity Increased
Previous
42.86%
Current
46.65%
Delta
3.80%
Cash Generation Increased
Previous
18.63%
Current
34.19%
Delta
15.56%
Inventory Pressure Increased
Previous
21.33%
Current
22.66%
Delta
1.34%
Margin Increased
Previous
15.07%
Current
15.87%
Delta
0.80%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.